today announced two upcoming presentations at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK.

The oral ePoster presentation will include results from a Phase 2a human challenge study of EDP-323, a first-in-class, oral, non-nucleoside small-molecule inhibitor of the RSV polymerase (L-protein), ...

Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the ...

"We are thrilled that our research involving our selective degrader programs for SMARCA2, CDK2 and IKZF2 will be showcased prominently at AACR 2025, including during two oral presentations ...

The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation.

Oral presentation by Christian Mirescu, Ph.D., Senior Vice President, Neuroimmunology: Small Molecule TREM2 Agonists as Next-Generation Therapeutics for Alzheimer’s Disease Date and Time ...

In contrast to an oral presentation, a “poster” is a visual representation of the research project that must convey the essence of your message. In effect, it “talks” for the researcher. The poster ...